Fast-Acting Biofilm Removal Combination
Biofilm-associated infections, such as catheter-associated urinary tract infections (CAUTIs), impose a substantial burden on healthcare systems, so the development of effective therapies is crucial. According to Future Market Insights, the global market for treating CAUTIs was valued at USD$83.2 billion in 2022 and is projected to reach USD$171.56 billion by 2033, with a steady CAGR of 6.8%. This presents a notable business opportunity for the development of innovative solutions aimed at preventing or treating CAUTIs.
Our team has developed a novel combination of two chemicals, SC5005 and DHA. This combination demonstrates a rapid and broad-spectrum activity in eradicating bacterial and fungal biofilms on patient foley catheters. Importantly, SC5005 + DHA is not cytotoxic and does not induce bacterial resistance, making it a potential solution for eradicating catheter biofilms to prevent CAUTIs.